Tag
Obesity increases the number of misoprostol doses needed for active labor during induction, with buccal dosing requiring more doses than vaginal, highlighting implications for individualized labor management.
Mazdutide, a once-weekly glucagon and GLP-1 receptor dual agonist, delivers clinically meaningful weight reduction in adults with obesity or overweight, with higher doses yielding superior outcomes and manageable safety profiles.
In the SELECT trial, semaglutide significantly lowered hsCRP levels and major cardiovascular events in patients with established atherosclerotic cardiovascular disease and overweight or obesity, suggesting inflammation reduction as a possib
This study reveals that weight gain exceeding 5% in MASLD patients increases liver-related event risks and liver stiffness, whereas weight loss improves liver stiffness and may reduce adverse outcomes, especially with obesity reversal.
This review synthesizes evidence linking smartphone acquisition and use at age 13 to depression, obesity, and sleep insufficiency at age 14, highlighting that use intensity rather than mere acquisition mediates health risks, with behavioral
This study investigates how semaglutide exposure before and during pregnancy affects gestational weight gain and key pregnancy outcomes in women with overweight or obesity, highlighting increased risks that may stem from treatment discontin
A clear, evidence-based summary of the 2026 SGO–SAGES clinical practice statement recommending integration of metabolic and bariatric surgery into multidisciplinary care for women with EIN and endometrial cancer.
This review synthesizes evidence from the STEP 12 trial and related studies demonstrating that once-weekly semaglutide 2.4 mg significantly reduces bodyweight and improves cardiometabolic outcomes in Chinese adults with overweight or obesit
The American College of Physicians’ 2026 position paper calls for comprehensive payer coverage, healthy food access, bias reduction, and research to tackle adult obesity through multisector public policy.
A medically supervised preoperative weight loss program is feasible and leads to significant short-term weight reductions in women with obesity and atypical hyperplasia or low-grade endometrial carcinoma. Further research is necessary to co
The ENDO trial demonstrates that the EndoBarrier duodenal-jejunal bypass liner significantly improves glycemic control and induces meaningful weight loss in patients with poorly controlled type 2 diabetes and obesity, with an acceptable saf
Emerging obesity pharmacotherapies targeting entero-pancreatic hormones deliver substantial weight loss and improve multiple obesity-related complications, heralding a treat-to-target paradigm in obesity management with personalized, compli
This study delineates phenotypic and polysomnographic differences in children with extreme versus very severe OSA, highlighting the critical role of obesity and oxygenation metrics in identifying extreme cases.
A NIDDK workshop highlighted the crucial role of real-world evidence in addressing gaps about GLP-1 receptor agonists’ safety, effectiveness, adherence, and economic impact to improve clinical and regulatory decision-making.
Researchers developed and validated the FMO score, a noninvasive, cost-effective tool to identify at-risk metabolic dysfunction-associated steatohepatitis (MASH) in obese patients, showing strong predictive performance across multiple inter
This study examines how obesity and alcohol consumption jointly impact diabetes risk over time in an Asian cohort, highlighting differences in interaction measures and implications for diabetes prevention.
Analyzing 54 million adults in England reveals rising obesity rates from 2019-2025, disproportionately affecting socioeconomically deprived, ethnic minority, and younger adult groups, with widening inequalities intensified during the COVID-
A retrospective cohort study evaluating 1-year weight loss, glycaemic control, and safety outcomes among adults with obesity and type 2 diabetes treated with semaglutide, tirzepatide, or sleeve gastrectomy, highlighting higher efficacy with
In a large TriNetX study, GLP-1 receptor agonists were associated with better overall survival and lower locoregional recurrence than bariatric surgery alone in obese postmenopausal women with stage 0-III breast cancer.
A large real-world study found GLP-1 receptor agonists were associated with better survival and lower locoregional recurrence than bariatric surgery in postmenopausal women with obesity and breast cancer.
